CompletedNot Applicable

Accexible Speech Analysis for MCI Detection and Monitoring in Colombia

Colombia114 participantsStarted 2022-05-22

Plain-language summary

Mild Cognitive Impairment (MCI) is frequently underdiagnosed due to its subtle clinical presentation. This study evaluates the diagnostic performance of AcceXible, a speech analysis-based machine learning platform, compared to the Montreal Cognitive Assessment (MoCA) for MCI detection and monitoring in Colombian patients. A diagnostic test accuracy study will be conducted within a primary care setting (EPS Sanitas), including prior validation of the AcceXible protocol in the Colombian healthcare context. The study pursues two primary aims: (1) to validate the AcceXible tool in a Colombian population, and (2) to demonstrate that AcceXible achieves high diagnostic accuracy for early MCI detection and longitudinal monitoring relative to the MoCA.

Who can participate

Age range60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Ability to independently operate a mobile or portable device with internet connectivity and integrated microphone * Provision of voluntary written informed consent prior to study participation Exclusion Criteria: * Diagnosed psychiatric disorder or cognitive impairment not attributable to neurodegenerative etiology * Visual impairment sufficient to preclude reading on-screen text or perceiving visual stimuli * Illiteracy * Hearing impairment sufficient to preclude comprehension of verbal instructions or detection of auditory test-onset cues

What they're measuring

Diagnostic accuracy of acceXible compared to MoCA for MCI detection

Timeframe: Baseline

Trial details

NCT IDNCT07553117

SponsorAccexible

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-06-17

View on ClinicalTrials.gov More MCI trials